CHIREC-Hôpital Delta, Brussels, Belgium.
Groupe Hospitalier Saint Vincent, Strasbourg, France.
Curr Opin Oncol. 2024 Jul 1;36(4):248-252. doi: 10.1097/CCO.0000000000001027. Epub 2024 Feb 23.
Nearly half of cancer patients use complementary therapies alongside the conventional cancer treatment. This clinical reality is a challenge for the medical team mainly to guarantee patient's safety. The evolution from Supportive Care to Integrative oncology is taking shape.
Integrative oncology, a new field in cancer care, combines conventional supportive care and validated complementary approaches. The first part of this review is to highlight the process of validation of one of the most popular complementary medicines among European cancer patients: homeopathy. It seems to be a well tolerated and useful complementary approach in integrative cancer care. The second part shows through the example of stage IV lung cancer the transition from conventional supportive care to integrative oncology with a benefit for their quality of life and survival.
The future of supportive cancer care seems to lead towards a move from coexistence of conventional care and complementary approaches to a combination of both in integrative oncology. This would require new skills among caregivers, specific academic training and adapted studies. Further research is needed to highlight the benefits in the specific field of integrative cancer care.
近一半的癌症患者在接受常规癌症治疗的同时还会使用补充疗法。这种临床现实对医疗团队来说是一个挑战,主要是为了保证患者的安全。从支持性治疗到肿瘤整合医学的转变正在形成。
肿瘤整合医学是癌症治疗中的一个新领域,它结合了常规的支持性治疗和经过验证的补充方法。这篇综述的第一部分重点介绍了在欧洲癌症患者中最受欢迎的补充药物之一——顺势疗法的验证过程。顺势疗法似乎是一种耐受性良好且有用的补充方法,可以用于肿瘤整合医学。第二部分通过 IV 期肺癌的例子展示了从常规支持性治疗向肿瘤整合医学的转变,这对他们的生活质量和生存都有好处。
支持性癌症治疗的未来似乎是从常规治疗和补充方法的共存转向整合医学中的两者结合。这将需要护理人员具备新的技能、特定的学术培训和适应性研究。需要进一步的研究来突出整合癌症治疗特定领域的益处。